Real-world use of nirmatrelvir–ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study-Reference-Cited by-同舟云学术

Real-world use of nirmatrelvir–ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study

Published:2023-06 Issue:6 Volume:23 Page:696-705
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Aggarwal Neil R,Molina Kyle C,Beaty Laurel E,Bennett Tellen D,Carlson Nichole E,Mayer David A,Peers Jennifer L,Russell Seth,Wynia Matthew K,Ginde Adit A

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference27 articles.

1. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19;Owen;Science,2021

2. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19;Hammond;N Engl J Med,2022

3. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study;Nyberg;Lancet,2022

4. COVID-19 “rebound” associated with nirmatrelvir/ritonavir pre-hospital therapy;Coulson;J Infect,2022

5. Hospitalization and emergency department encounters for COVID-19 after paxlovid treatment—California, December 2021–May 2022;Malden;MMWR Morb Mortal Wkly Rep,2022

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Machine Learning Method for Allocating Scarce COVID-19 Monoclonal Antibodies;JAMA Health Forum;2024-09-13

2. Real-world evaluation of early remdesivir in high-risk COVID-19 outpatients during Omicron including BQ.1/BQ.1.1/XBB.1.5;BMC Infectious Diseases;2024-08-08

3. Clinical real-world effectiveness of nirmatrelvir/ritonavir for the treatment of SARS-CoV-2 infection: A meta-analysis;Tungs' Medical Journal;2024-08-08

4. Comparing the effectiveness of molnupiravir and nirmatrelvir‐ritonavir in non‐hospitalized and hospitalized COVID‐19 patients with type 2 diabetes: A target trial emulation study;Diabetes, Obesity and Metabolism;2024-08-07

5. Cost-effectiveness of nirmatrelvir/ritonavir for high-risk adult outpatients with COVID-19 in Japan;Journal of Infection and Chemotherapy;2024-08